- A systematic review summarizes resting-state and sleep EEG alterations as biomarkers in Huntington’s disease.1
- EEG biomarkers and resting-state or sleep EEG are electrophysiology methods with review-level evidence.1 1
Weekly enrichment (2026-07-20)
- The systematic review (Clinical Neurophysiology, February 2026; PMID 41747657) synthesized EEG biomarkers across resting-state, sleep, medication-response and clinical-correlation studies in Huntington’s disease and premanifest gene carriers.23
- It searched PubMed, Web of Science and EMBASE and included 23 studies: 20 resting-state, 6 sleep, 3 medication-related and 20 clinical-correlation (categories overlap); most included a control group and were small.24
- Resting-state EEG commonly showed reduced alpha power and altered delta activity in patients, while theta- and beta-band results were more variable.24
- Sleep EEG studies consistently showed reduced theta power; EEG was largely unaffected by medication, aside from higher spindle density in unmedicated patients in one study.2
- Greater cognitive and motor impairment was associated with reduced alpha and theta power, with abnormalities detectable even in premanifest stages.24
- The authors conclude EEG is a promising noninvasive biomarker for early diagnosis and monitoring but call for larger samples and standardized methods.23
- Supporting microstate work (20 unmedicated patients vs 20 controls) found reduced connectivity, increasing dimensionality with severity, and class A/B increases with class C/D decreases correlating with cognition.5
- A mechanistic EEG review frames Huntington’s as an excitation/inhibition imbalance and reports polysomnography abnormalities in premanifest carriers (sleep efficiency 81% ± 8% vs 96% ± 4% in controls, ~40% more nocturnal awakenings, and REM percentage falling from 22% to 16%).6